Regen BioPharma Inc (RGBP)

[cash4]

Regen BioPharma Inc (OTCMKTS: RGBP/RGBPP) Northbound as Biotech Grows Valuable Patent Portfolio & Grants 2 Licenses to Oncology Pharma for $1.9 Million

https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-northbound-as-biotech-grows-valuable-patent-portfolio-grants-2-licenses-to-oncology-pharma-for-1-9-million/

By
Boe Rimes
December 31, 2021

Released on Sunday, January 2, 2022




Regen BioPharma Inc (OTCMKTS: RGBP) has been moving steadily northbound in recent trading as speculators move back into the stock and bid it higher. On Friday the stock was up 26% on $1.9 million in dollar volume. This comes after the Company’s CEO David Koos issued a letter to shareholders which summarized some of the recent accomplishments including recently going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing the Companys valuable patent portfolio as well as granting two licensees to Oncology Pharma for which RGBP was paid $1,905,000 in cash and securities.



RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.

Regen BioPharma Inc (OTCMKTS: RGBP) “pink current” operating out of San Diego, California is a publicly traded biotechnology company that was founded in 2012 focused on the immunology and immunotherapy space. Regen BioPharma is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. RGBP is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through the Company’s patented molecular targeting approaches (BORIS), & repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). Currently RGBP has 2 investigational new drug applications (IND) filed with the FDA and 3 products in preclinical development based on the newly discovered cancer stem cell gene target



The big story on RGBP is its valuable intellectual property portfolio consisting of a large and growing number of patents. The Company’s CEO David Koos has been working hard in recent months getting all the expired Patents updated a logical step for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline. Recently RGBP has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office and been issued several new patents. CEO David Koos is a highly accomplished executive who has been working in the financial markets for 3 decades. He has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance.

Last month RGBP entered into an LOI to acquire Canary Oncoceutics, Inc., a new company developing in vitro precision oncology tests using cellular technology. The acquisition contemplated by the non-binding LOI is contingent upon several factors including, but not limited to, completion of due diligence, the completion of final negotiations, and execution of a definitive agreement. It is presently contemplated that in order for this acquisition to close, Regen must raise $50 million to support the development of the diagnostic platform. Canary Oncoceutics, Inc. is developing a precision oncology testing platform that will complement existing cancer genomic testing.




To Find out the inside Scoop on RGBP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RGBP

Cancer genomic testing involves analyzing a sample of a cancer tumor to see how active certain genes are and if they are abnormally modified. The activity level of these genes affects factors including how likely the cancer is to grow and spread. By identifying the genetic alterations that are unique to a patient’s individual cancer, doctors are able to identify specific drugs designed to target those mutations. However, the list of drugs generated by genomic testing may be quite extensive and different patients respond differently to the same drug. Canary Oncoceutics, Inc. is developing tests that take those recommendations and test them on a patient’s tumor in a laboratory setting thereby allowing doctors to refine the list of recommendations generated through genomic testing down to those drugs or drug combinations which will work best on that specific patient. “Companion diagnostics in precision oncology is where the future of cancer treatment is heading. The global cancer diagnostics market was $168 billion in 2020 and is expected to reach $280 billion by 20281”, said David Koos at the time.



On December 30 RGBP CEO David Koos wished shareholders a happy holiday season in a letter to shareholders stating: “When I returned to Regen on March 23, 2021 in order to serve as Chairman and Chief Executive Officer, I found myself at the helm of a company on the verge of collapse. We were behind in bills, at risk of losing patent protection on valuable IP, and delinquent in our SEC filing obligations. Worse of all we were being sued by Chemdiv-our Contract Research Organization- in a complaint seeking damages of $1,200,000 which also threatened our ownership rights to valuable intellectual property

As the year progressed, we faced the challenges that lay before us and conquered them. Regen has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, been issued several new patents, entered into two non-related party licensing agreements and became current in its SEC filing obligations eliminating the risk that the public trading market for both the common and Series A preferred shares would disappear.

Becoming current in our SEC reporting obligations after such a long delinquency was a significant achievement. Recent amendments to SEC Rule 15c2-11 threatened the public trading status of delinquent issuers. I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financials. During the quarter ended June 30, 2021 the Company was paid $1,905,000 in cash and securities resulting from two licenses granted in April, 2021 to Oncology Pharma, Inc. (“ONPH”).

Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen’s shareholders and I expect to identify a contract research organization that will help us move the Company’s intellectual propriety towards clinical trials.




RGBP has been moving steadily northbound in recent trading as speculators move back into the stock and bid it higher. On Friday the stock was up 26% on $1.9 million in dollar volume. This comes after the Company’s CEO David Koos issued a letter to shareholders which summarized some of the recent accomplishments including recently going “pink current” and becoming fully compliant, settlings the lawsuit with Chemdiv, growing the Companys valuable patent portfolio as well as granting two licensees to Oncology Pharma for which RGBP was paid $1,905,000 in cash and securities. RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; according to many investors It appears there may be a possible merger acquisition looming with Precigen or another big pharma which would make sense as the CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on Nasdaq with a Market Cap of $766 million. RGBP is in the same clinical therapeutic niche market of Oncology-Immunology candidate drug development that Precigen is in including the same mRNA vaccine technology so logically speaking it would make sense if PGEN straight up buys-out RGBP or does a merger acquisition and the motive to do this are the numerous valuable Patents RGBP owns that address enormous billion-dollar markets.